Suppression of proliferation of poliovirus and porcine parvovirus by novel phenoxazines, 2-amino-4,4α-dihydro-4α-7-dimethyl-3H-phenoxazine-3- one and 3-amino-1,4α-dihydro-4α-8-dimethyl-2H-phenoxazine-2-one

Biological and Pharmaceutical Bulletin

Volumn 28, Issue 5, 2005, Pages 905-907

  Iwata, Akiko ^a   Yamaguchi, Teruhide ^a   Sato, Kouei ^b   Yoshitake, Noriko ^c   Tomoda, Akio ^c  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b Inst of Saitama Red Cross Center   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Phenoxazine; Poliovirus; Porcine parvovirus

Indexed keywords

2 AMINO 4,4ALPHA DIHYDRO 4ALPHA 7 DIMETHYL 3H PHENOXAZINE 3 ONE; 3 AMINO 1,4ALPHA DIHYDRO 4ALPHA 8 DIMETHYL 2H PHENOXAZINE 2 ONE; PHENOXAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; HERPES SIMPLEX VIRUS 1; HOST CELL; INOCULATION; NONHUMAN; POLIOMYELITIS VIRUS; PORCINE PARVOVIRUS; SIMIAN VIRUS 40; SINDBIS VIRUS; VERO CELL; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACACA MULATTA; OXAZINES; PARVOVIRUS; POLIOVIRUS; SIMIAN VIRUS 40; SWINE; VERO CELLS;

EID: 19644366708     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.28.905     Document Type: Article

References (16)

1. Schaffer H. J., Beauchamp L., de Miranda P., Elion G. B., Bauer D. J., Collins P., Nature (London), 272, 583-585 (1978).
2. Schmidtke M., Schnittler U., Jahn B., Dahse H., Stelzner A., J. Virol. Methods, 95, 133-143 (2001).
3. Tomoda A., Yamaguchi J., Kojima H., Amemiya H., Yoneyama Y., FEBS Lett., 196, 44-48 (1986).
4. Tomoda A., Hamashima H., Arisawa M., Kikuchi T., Tezuka Y., Koshimura S., Biochim. Biophys. Acta, 1117, 306-314 (1992).
5. Tomoda A., Arisawa M., Koshimura S., J. Biochem. (Tokyo), 110, 1004-1007 (1991).
6. Mori H., Honda K., Ishida R., Nohira T., Tomoda A., Anti-Cancer Drugs, 11, 653-657 (2000).
7. Koshibu-Koizumi J., Akazawa M., Iwamoto T., Takasaki M., Mizuno F., Kobayashi R., Abe A., Tomoda A., Hamatake M., Ishida R., J. Cancer Res. Clin. Oncol. 128, 363-368 (2002).
8. Akazawa M., Koshibu-Koizumi J., Iwamoto T., Takasaki M., Nakamura M., Tomoda A., Tohoku J. Exp. Med., 196, 185-192 (2002).
9. Gao S., Takano T., Sada K., He J., Noda C., Hori-Tamura N., Tomoda A., Yamamura H., Br. J. Pharmacol., 137, 749-755 (2002).
10. Enoki E., Sada K., Qu X., Kyo S., Shahjahan Miah S. M., Hatani T., Tomoda A., Yamamura H., J. Pharm. Sci., 94, 329-333 (2004).
11. Iwata A., Yamaguchi A., Sato K., Izumi R., Tomoda A., Tohoku J. Exp. Med., 200, 161-165 (2003).
12. Kawamura H., Fujita T., Imada T., Nippon Juigaku Zasshi, 50, 803-808 (1988).
13. Johnson K. L., Sarnow S. P., J. Virol., 65, 4341-4349 (1991).
14. Satoh K., Iwata A., Murata M., Hikata M., Hayakawa T., Yamaguchi T., J. Virol. Methods, 114, 111-119 (2003).
15. Tang J., Colacino J. M., Larsen S. H., Spitzer W., Antiviral Res., 13, 313-326 (1990).
16. Huang H. C., Chu S. H., Chao P. D. L., Eur. J. Pharmacol., 198, 211-213 (1991).